OncoMatch/Clinical Trials/NCT07193511
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Is NCT07193511 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including AVZO-103 and Combination Agent for solid tumor cancer.
Treatment: AVZO-103 · Combination Agent — This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Urothelial Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Avenzo Therapeutics Recruiting Site · Orlando, Florida
- Avenzo Therapeutics Recruiting Site · Boston, Massachusetts
- Avenzo Therapeutics Recruiting Site · Myrtle Beach, South Carolina
- Avenzo Therapeutics Recruiting Site · Nashville, Tennessee
- Avenzo Therapeutics Recruiting Site · Austin, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07193511 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages